Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
Malignant neoplasm of prostate
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
There are two transcriptional variants of DPYSL3 gene in human genome, of which the variant 2 is the dominant transcript (DPYSL3v2, CRMP4a) but is also significantly down-regulated in primary prostate cancers.
|
27014974 |
2016 |
Malignant neoplasm of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We found genome-wide significant (P < 5.0 × 10(-8)) evidence for three additional lung cancer susceptibility loci at 10p14 (rs1663689, close to GATA3, P = 2.84 × 10(-10)), 5q32 (rs2895680 in PPP2R2B-STK32A-DPYSL3, P = 6.60 × 10(-9)) and 20q13.2 (rs4809957 in CYP24A1, P = 1.20 × 10(-8)).
|
22797725 |
2012 |
Carcinoma of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We found genome-wide significant (P < 5.0 × 10(-8)) evidence for three additional lung cancer susceptibility loci at 10p14 (rs1663689, close to GATA3, P = 2.84 × 10(-10)), 5q32 (rs2895680 in PPP2R2B-STK32A-DPYSL3, P = 6.60 × 10(-9)) and 20q13.2 (rs4809957 in CYP24A1, P = 1.20 × 10(-8)).
|
22797725 |
2012 |
Primary malignant neoplasm of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We found genome-wide significant (P < 5.0 × 10(-8)) evidence for three additional lung cancer susceptibility loci at 10p14 (rs1663689, close to GATA3, P = 2.84 × 10(-10)), 5q32 (rs2895680 in PPP2R2B-STK32A-DPYSL3, P = 6.60 × 10(-9)) and 20q13.2 (rs4809957 in CYP24A1, P = 1.20 × 10(-8)).
|
22797725 |
2012 |
Autism Spectrum Disorders
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Whole-exome sequencing detected a de novo variant (S541Y) of CRMP4 in a male ASD patient.
|
29196732 |
2017 |
Lentivirus Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The stable prostate cancer cells overexpressing the CRMP4 gene were constructed using lentivirus infection.
|
25338524 |
2015 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our data demonstrated that saRNA-based DPYSL3 gene enhancement is capable of suppressing tumor metastasis in prostate cancer, which provides a potential therapeutic approach for cancer management.
|
28639202 |
2019 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Characterization of the roles of dihydropyrimidinase-like 3 in relation to cancer cell adhesion and migration in vitro, and metastasis in vivo was performed using a series of functional analyses, including those employing multiple reaction monitoring proteomic analysis.
|
24339867 |
2013 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A metastatic lung tumor model in which the stable DPYSL3 knockdown LLC cells were injected through tail vein was used to analyze the role of DPYSL3 in tumor metastasis in vivo.
|
29514686 |
2018 |
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated CRMP4 inhibits prostate cancer cells growth in the nude mouse bone microenvironment and this effect may relate with regulation of NRP1 and Noggin expression.
|
25338524 |
2015 |
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrated that saRNA-based DPYSL3 gene enhancement is capable of suppressing tumor metastasis in prostate cancer, which provides a potential therapeutic approach for cancer management.
|
28639202 |
2019 |
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
CRMP4 promoter methylation in diagnostic biopsies could be a robust biomarker for LNM in PCa.
|
28122909 |
2017 |
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
Thus, in this study, we show new function of CRMP4 as a metastasis-suppressor in PCa.
|
20543870 |
2010 |
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer.
|
27475326 |
2016 |
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Cell migration and invasion assays were performed to determine the role of DPYSL3 in LLC cells' migration and invasion changes.
|
29514686 |
2018 |
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, dihydropyrimidinase-like 3 was found to interact with Ezrin, which has important roles in cell adhesion, motility, and invasion, while that interaction promoted stabilization of an adhesion complex consisting of Ezrin, c-Src, focal adhesion kinase, and Talin1.
|
24339867 |
2013 |
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Our previous study showed collapsin response mediator protein 4 (CRMP4) gene inhibited prostate cancer migration and invasion.
|
25338524 |
2015 |
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
CRMP4 knockdown using siRNA reduced cellular invasion, but did not affect proliferation.
|
22805864 |
2013 |
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated CRMP4 inhibits prostate cancer cells growth in the nude mouse bone microenvironment and this effect may relate with regulation of NRP1 and Noggin expression.
|
25338524 |
2015 |
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
CRMP4 promoter methylation in diagnostic biopsies could be a robust biomarker for LNM in PCa.
|
28122909 |
2017 |
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Thus, in this study, we show new function of CRMP4 as a metastasis-suppressor in PCa.
|
20543870 |
2010 |